Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027
Prime Medicine Inc PRME
$2.92
▼ -3.31%
($-0.10)
⬇️ Below Yest. Low
🔥 High Short Interest
🎢 High Beta
📅 Earnings This Week
Open
$3.03
Prev Close
$3.02
Day Range
$2.91 – $3.04
52W Range
$2.67 – $6.94
Market Cap
$527.40M
Beta
2.29
EPS (TTM)
$-1.26
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-10-20 |
| Shares Out. | 180,620,000 |
| Website | primemedicine.com/ ↗ |
| Phone | 13026587581 |
| Employees | 146 |
| Revenue | $856,000 |
| Gross Profit | $856,000 |
| Net Income | -$49.1M |
| Free Cash Flow | -$158.7M |
| Total Assets | $294.7M |
| Total Liabilities | $218.0M |
| Equity | $76.7M |
About Prime Medicine Inc
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Prime Medicine Inc is a publicly traded company under the ticker symbol PRME on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)